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TRANSLATIONAL RELEVANCE 26
Breast cancer (BC) is a heterogeneous disease driven by molecular changes of genetic and 27 epigenetic nature. By screening for genome-wide DNA methylation changes in BC, we 28
identified Cysteine Dioxygenase Type 1 (CDO1) as a DNA hypermethylated gene. We show 29 that CDO1 is frequently DNA methylated in breast primary tumors and that this event is 30 associated with adverse clinical features and poor prognosis. Based on the suggested role 31 for CDO1 in the oxidative stress response of cancer cells, we examined its role in the 32 resistance to the reactive oxygen species (ROS)-generating chemotherapeutic class of 33 anthracyclines. We found that restoration of CDO1 function in BC cells alters the oxidative 34 stress response in a way that it leads to sensitization to anthracylines. We further provide 35 potential clinical implications for this finding by showing that priming with 5-azacytidine of BC 36 cells with epigenetically silenced CDO1 increases the sensitivity to anthracycline therapy. 37
This finding provides a potential clinical strategy to overcome resistance to this drug and 38 DNA methylation of CDO1 may be useful as a marker to select patients for priming with 5-39 azacytidine. 40 associated silencing of CDO1 in BC is frequent (60%), cancer-specific and correlates with 50 disease progression and outcome. CDO1 function can alternatively be silenced by repressive 51 chromatin, and we describe protein damaging missense mutations in 7% of tumors without 52 DNA methylation. Restoration of CDO1 function in BC cells increases levels of ROS and 53 leads to reduced viability and growth, as well as sensitization to anthracycline treatment. 54
Priming with 5-azacytidine of BC cells with epigenetically silenced CDO1 resulted in restored 55 expression and increased sensitivity to anthracyclines. Conclusion: We report that silencing 56 of CDO1 is a critical epigenetic event which contributes to the survival of oxidative stressed 57 BC cells through increased detoxification of ROS and thus leads to resistance to ROS-58 generating chemotherapeutics including anthracyclines. Our study demonstrates the 59 importance of CDO1 inactivation in BC and its clinical potential as a biomarker and 60 therapeutic target to overcome resistance to anthracyclines.
INTRODUCTION 62
Loss of proper tumor suppressor function leads to the initiation and progression of human 63 cancer (1) and aberrant epigenetic alterations including DNA promoter hypermethylation can 64 be responsible for such functional loss (2) . Techniques to analyze genome-wide DNA 65 methylation have become useful tools to identify hundreds of new candidate DNA 66 hypermethylated genes in cancer. Comprehensive functional analyses can provide an 67 understanding of the biological significance of the vast amount of DNA methylation data 68 generated, allowing for the discovery of novel tumor suppressor genes and molecular 69 mechanisms underlying tumor growth control, and biomarkers for early detection, prognosis 70
and response to therapeutic agents in cancer (3-7). 71
Cysteine Dioxygenase Type 1 (CDO1), recently identified as a candidate hypermethylated 72 gene within the functional BC hypermethylome (7), is a non-heme iron dioxygenase (8) . 73 CDO1 determines the flux between cysteine catabolism and glutathione synthesis (9) by 74 and contributes to survival of oxidative stressed BC cells and their resistance to 101 anthracyclines through reducing cellular ROS levels. 102
MATERIAL AND METHODS 103

Cell Culture and Drug Treatment 104
Cell lines were purchased from American Type Culture Collection (ATCC) and cultured in 105 appropriate media (Mediatech) supplemented with 10% FBS (Atlanta Biologicals) and 1x 106
Penicillin-Streptomycin (Mediatech) at 37°C in 5% CO 2 atmosphere. The HCT116 derivative 107 cell line lacking the major DNA methyltransferases DNMT1 and 3b (DNMT1 -/-and DNMT3b -/-; 108 Double Knockout or DKO) was maintained as previously described (28). Drug treatment with 109 5-aza-2'-deoxycytidine (DAC) and Trichostatin A (TSA) were carried out as previously 110 described (7). For glutathione depletion, cells were treated with 0.5 mM buthionine 111 sulfoximine (BSO). Doxorubicin was supplemented in doses ranging from 0.078 µM to 20 µM 112 to determine LD50 dosage and 5-azacytidine in doses ranging from 1 µM to 5 µM, chosen for 113 maximal CDO1 expression. 114
Patient Samples 115
Primary tumor specimen and normal breast tissues from cancer-free donors were obtained 116 Insurance Portability and Accountability Art compliance. Genome-wide methylation and 120 expression data of primary tissues were also utilized from The Cancer Genome Atlas 121 (TCGA) (http://cancergenome.nih.gov/). 122
Gene Expression, Methylation Analysis, and ChIP 123 RNA was extracted using RNeasy Mini Kit (Qiagen) or purchased from Stratagene (normal 124 tissues). For RT and real-time RT-PCR, 1 μg RNA was reverse-transcribed into cDNA using 125
Research. were generated using the T-REx System (Invitrogen). Expression of CDO1 was induced with 155 0.5 μg/ml Doxycycline. 156
Western Blot 157
CDO1 protein expression was detected in whole cell protein extracts with either α-V5 158 Geneticin/G418 (Invitrogen) for 28 days and counted after staining with 0.005% crystal violet. 166
Cell Viability Assay 167
Cell viability was measured using CellTiter96 R kit (Promega). Cells were incubated in MTS 168 reagent for 4 hrs at 37 °C. Absorbance was measured at 490 nm. 169
Measurement of ROS Production 170
ROS production was measured using CM-H2DCFDA probe (Invitrogen). Cells were loaded 171 with 5 µM CM-H2DCFDA probe in phenol-red free and serum-free media for 1 hr. 172
Fluorescence was measured at 493 nm excitation and at 523 nm emission. 173
Statistics 174
Research. were performed using the STATA 9.2 software package. 181
RESULTS 182
Silencing of CDO1 is associated with DNA promoter hypermethylation or repressive 183 figure 2D . 239 DNA methylation-associated silencing of CDO1 occurs in multiple cancer types 240
We expanded our efforts to analyze the DNA methylation and expression status of CDO1 in 241 other tumor types. We assayed the CDO1 expression status in normal tissues as well as in 242 three corresponding cancer cell lines (ovary, lung, pancreas and liver). CDO1 was expressed 243 in all tested normal tissues but not expressed in association with DNA promoter methylation 244 in the corresponding cancer cell lines with the exception of HEPG2 liver cancer cells, in 245 which the CDO1 promoter is unmethylated ( Supplementary Figure 2A) . We further 246 determined CDO1 methylation status in primary tumor specimens of these tumor types. We 247 found CDO1 to be commonly methylated (>60%) in ovary, lung and pancreas cancer 248 Figure 2D) . 254
Tumor-specific point mutations within the CDO1 gene have a predicted protein damaging 255 effect 256
To test whether CDO1 may be inactivated by ways other than epigenetic mechanisms, we 257 screened for mutations within the CDO1 gene in 60 primary BCs (unmethylated CDO1 258 promoter status). We found 9 SNPs in 10 patients (17%) ( Table 1) 
effect (values near 1 are predicted to be deleterious) with the highest possible probability. 264
The Y157F mutation was introduced as a control into this assay. This mutation, within the 265 catalytic center of the CDO1 enzyme, has been shown to reduce the enzymatic activity to up 266 to ∼95% (32). A calculated protein damaging score of 0.999 reliably predicted for the 267 experimental proven loss of function caused by this mutation. Subsequently, we confirmed 268 the three mutations with the highest damage scores as tumor-specific by screening normal 269 tissue of the four patients that harbored these mutations in their tumor. Supplementary 270 of ROS production that return to baseline at 48 hrs post treatment ( Figure 3C ). This suggests 297 that CDO1 protein level may decrease in response to increasing ROS production as an 298 antioxidant adaptive mechanism. 299
CDO1 induced reduction in ROS detoxification sensitizes BC cells to anthracycline treatment 300
Anthracyclines, such as Doxorubicin, are cytotoxic ROS-generating chemotherapeutic 301 agents (27) widely used in the treatment of BC. Resistance to these agents is believed to be 302 Figure 5A and 316 5B). To further implicate the re-expression of CDO1 in this synergistic effect, we pretreated 317
MDA-MB-231 cells with Doxycycline-induced CDO1 expression with 5-azacytidine and 318
subsequently with Doxorubicin. We observed no difference in viability between cells that 319 overexpressed CDO1 and were pretreated with 5-azacytidine and cells that overexpressed 320 CDO1 and were not pretreated with 5-azacytidine ( Figure 5C and 5D) . 321
DISCUSSION 322
In the current study we show that aberrant DNA methylation of CDO1 is a tumor-specific and 323 frequent (~60%) event in BC that is associated with gene silencing. We observed a stage-324 dependent increase in CDO1 methylation frequency that significantly correlates with disease 325 progression and outcome. Loss of CDO1 expression by DNA methylation is also a frequent 326 event in multiple other cancer types. In addition to other studies that uncovered CDO1 as 327 aberrantly methylated and silenced in colorectal cancer (34) and malignant glioma (35), we 328
Research. loss of CDO1 expression might be a useful marker for prediction of resistance to this therapy 370 and for selection of patients for priming therapy with 5-azacytidine to overcome resistance. 371
Our data support that priming with 5-azacytidine of BC cells with epigenetically silenced 372 CDO1 may sensitize them to anthracycline therapy partly through the re-expression of 373
CDO1. 374
Given the inactivation of CDO1 by multiple mechanisms across multiple types of cancer, a 375 pattern that has been observed for important tumor growth suppressive genes, the reduced 376 
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